This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kuros Biosciences Ltd.,
Drug Names(s): CYT002-NicQb, Nicotine-Qbeta, NicQb, NIC002
Description: NIC-002 is a therapeutic vaccine comprised of nicotine chemically coupled to the virus-like particle Qb. It works by inducing nicotine-specific antibodies that bind to nicotine in the bloodstream. As the complex of nicotine attached to an antibody is too large to cross the bloodbrain barrier, nicotine uptake into the brain and the subsequent stimulation of nicotine-responsive nerve cells is believed to be reduced. In this way, the reward-inducing and addiction-driving stimulusof nicotine should be minimized and abstinence from smoking more easily achieved and maintained.
Cytos and Novartis
In April 2007, Cytos Biotechnology entered into an exclusive global commercial licenseagreement with Novartis to develop, manufacture and commercialize NIC002.Under the terms of the agreement, Novartis is granted world-wide exclusive rights forNIC002 and is responsible for late-stage clinical development, manufacturing, andcommercialization of the vaccine. In return, Cytos Biotechnology is eligible to receive up toCHF 600 million in upfront and potential development, regulatory approval and salesmilestone payments based on the successful development and commercialization of NIC002.In addition, Cytos Biotechnology will receive royalty payments on net sales of products.
In January 2013, Cytos announced that Novartis will discontinue the NIC002 project. As a result of the discontinuation, Novartis will terminate the license granted in 2007 and will return to Cytos the licensed rights pursuant to the provisions of the license...See full deal structure in Biomedtracker
Pink Sheet Weekly Trademark Review March 3, 2015
Additional information available to subscribers only: